NorPN: Intravenous Bolus of Phenylephrine vs. Norepinephrine in Preventing Hypotension After Spinal Anesthesia

Sponsor
University Tunis El Manar (Other)
Overall Status
Completed
CT.gov ID
NCT02854787
Collaborator
(none)
120
1
2
7
17.1

Study Details

Study Description

Brief Summary

The purpose of the study is to determine if an intravenous bolus of phenylephrine is more effective compared to an intravenous bolus of norepinephrine associated with crystalloid loading for maintaining blood pressure during a spinal anesthetic for a cesarean delivery. Prevention of low blood pressure has been shown to decrease nausea and vomiting during and after cesarean delivery under spinal anesthesia. For elective cesarean delivery, all participants will receive spinal anesthesia with a local anesthetic and sufentanil. This study plans to enroll 120 pregnant women. Patients will be randomly assigned according to a computer generated system to be in one of two groups.

Detailed Description

This study will be a prospective, randomized, active treatment controlled trial.

After written and informed consent are obtained, the study participants are randomly assigned using a computer generated table to 1 of 2 treatment groups prior to cesarean delivery.

Group A will consist of: An intravenous bolus of 0,2 mcg/Kg of norepinephrine to maintain systolic blood pressure (SBP) within 80-120% of baseline before the spinal.

Group B will consist of: An intravenous bolus of 100mcg of phenylephrine to maintain systolic blood pressure (SBP) within 80-120% of baseline before the spinal.

Patients will be admitted to holding area. Baseline arterial blood pressure and heart rate will be measured in supine position, with left uterine displacement. Baseline blood pressure will be calculated by taking the mean of three consecutive SBP measurements taken 5 minutes apart. 500 mL of Lactated Ringers solution will be administered immediately after induction of spinal anesthesia at the outflow rate of 100ml per hour.

The primary endpoint is the number of provider interventions needed to maintain the SBP within 100-120% of baseline for both groups. The secondary endpoint is nausea measured with each provider intervention after induction of spinal anesthesia, and immediately following delivery with 11 point verbal rating scale (0 = no nausea, 1 = nausea). Vomiting will be recorded whenever present during the surgical procedure.

Bradycardia (HR less than 50 BPM) will be treated with Atropine 0.4mg IV or ephedrine 3 mg - 12 mg IV bolus.

Study participants will receive a standard spinal anesthetic consisting of 0.5% hyperbaric bupivacaine (2 mL) plus sufentanil (5 mcg) at L3-4 or L4-5. Prior to surgical incision, the spinal sensory level will be tested to the bilateral T6-T4 dermatomal level. The patients will be positioned supine with a wedge placed under the right hip to avoid aortocaval compression. Both the patient and the researcher's assistant (who will collect data) will be blinded as to the administered Phenylephrine or norepinephrine bolus. The study will end when cesarean section is completed and the patient transferred to the post-operative care unit.

Measured variables will include systolic, diastolic and mean non-invasive blood pressure, the number and type of interventions for control of blood pressure, heart rate, incidence of nausea and vomiting (NV), incidence of arrhythmia and fetal cord blood analysis (pH) at delivery.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Prevention
Official Title:
Intravenous Bolus of Phenylephrine vs. Norepinephrine in Preventing Hypotension After Spinal Anesthesia for Cesarean Section
Study Start Date :
May 1, 2016
Actual Primary Completion Date :
Sep 1, 2016
Actual Study Completion Date :
Dec 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Phenylephrine

A bolus of 100 mcg

Drug: Phenylephrine
A bolus of 100 mcg

Active Comparator: Norepinephrine

A bolus of 0,2 mcg/kg

Drug: Norepinephrine
A bolus of 0,2 mcg/kg
Other Names:
  • Noraline
  • NoradrĂ©naline
  • Outcome Measures

    Primary Outcome Measures

    1. Maternal Blood Pressure [At time of surgery (right after spinal anesthesia until end of surgery)]

      Measurement of systolic, diastolic and mean, non-invasive blood pressure during cesarean section with an infusion of either Ephedrine or Norepinephrine

    Secondary Outcome Measures

    1. Hemodynamic Parameters - heart rate [At time of surgery (right after spinal anesthesia until end of surgery]

      mean heart rate during cesarean section with an infusion of either Ephedrine or Norepinephrine

    2. Hemodynamic Parameters - arrhythmia [At time of surgery (right after spinal anesthesia until end of surgery)]

      incidence of arrhythmic events during cesarean section with an infusion of either Ephedrine or Norepinephrine

    3. Vomiting [At time of surgery (right after spinal anesthesia until end of surgery)]

      incidence of Vomiting (V) during cesarean section with an infusion of either Ephedrine or Norepinephrine. Measure will be done according to a simple scale: 0= no vomiting; 1= vomiting

    4. mean pH of the fetal cord blood in each group [At time of birth]

      fetal cord blood analysis will be done immediately after delivery in order to determine the pH value ( ie: logarithm of the blood concentration of hydrogen ions H+)in each group

    5. Nausea [At time of surgery (right after spinal anesthesia until end of surgery)]

      cesarean section with an infusion of either Ephedrine or Norepinephrine. Measure will be done according to a simple scale: 0= no nausea; 1= nausea

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • of Anesthesiologists (ASA) Physical Status classification 1 and 2

    • Pregnant women with singleton pregnancy

    Exclusion Criteria:

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Tunis maternity and neonatology center, minisetry of public health Tunis Tunisia 1007

    Sponsors and Collaborators

    • University Tunis El Manar

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Ben marzouk Sofiene, MD, assistant professor, University Tunis El Manar
    ClinicalTrials.gov Identifier:
    NCT02854787
    Other Study ID Numbers:
    • UniversityTunis el manar
    First Posted:
    Aug 3, 2016
    Last Update Posted:
    Oct 26, 2017
    Last Verified:
    Jul 1, 2016
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Keywords provided by Ben marzouk Sofiene, MD, assistant professor, University Tunis El Manar
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 26, 2017